TheraCryf plc Releases Annual Report and Announces AGM

Evgen Pharma ( (GB:TCF) ) just unveiled an update.

TheraCryf plc has announced the posting of its Annual Report and Accounts for the year ending 31 March 2025, available on its website. The company will hold its AGM on 9 July 2025 at the Royal Society of Medicine in London, followed by an in-person presentation to discuss full-year results and progress on its Orexin antagonist program, inviting all shareholders to attend.

Spark’s Take on GB:TCF Stock

According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.

Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.

To see Spark’s full report on GB:TCF stock, click here.

More about Evgen Pharma

TheraCryf plc is a clinical stage drug development company focusing on neuropsychiatry and oncology, with a broad pipeline targeting brain disorders such as addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company aims to generate compelling data sets to achieve proof of concept and partner with larger pharmaceutical companies for trials and commercialization. It collaborates with major universities and hospitals and is headquartered in Alderley Park, Cheshire, trading on AIM in London under the ticker TCF.

Average Trading Volume: 4,404,054

Technical Sentiment Signal: Sell

Current Market Cap: £5.05M

Learn more about TCF stock on TipRanks’ Stock Analysis page.